KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761 · see citing works

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,932 · see citing works

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V. A., Hirsh, V., Leighl, N. B., Mezger, J. M., Archer, V. R., Moore, N., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5466 · Cited by 1,500 · see citing works

Ras in Cancer and Developmental Diseases

Fernández‐Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 959 · see citing works

Essential role for oncogenic Ras in tumour maintenance

Chin, L., Tam, A., Pomerantz, J. H., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 928 · see citing works

Antiangiogenic therapy in oncology: current status and future directions

Jayson, G. C., Kerbel, R. S., Ellis, L. M., & Harris, A. L. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01088-0 · Cited by 829 · see citing works

K-rasOncogene Activation as a Prognostic Marker in Adenocarcinoma of the Lung

Slebos, R. J. C., Kibbelaar, R. E., Dalesio, O., Kooistra, A., Stam, J., Meijer, C. J. L. M., Wagenaar, S. S., Vanderschueren, R. G. J. R. A., van Zandwijk, N., Mooi, W. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199008303230902 · Cited by 806 · see citing works

Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.

Rak, J. W., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1995) · PubMed · Cited by 762 · see citing works

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq020 · Cited by 638 · see citing works

The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis

Mascaux, C., Iannino, N., Martin, B., Paesmans, M., Berghmans, T., Dusart, M., Haller, A., Lothaire, P., Meert, A.-P., Noël, S., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602258 · Cited by 604 · see citing works

Mutational Activation of the K-rasOncogene

Rodenhuis, S., van de Wetering, M. L., Mooi, W. J., Evers, S. G., van Zandwijk, N., & Bos, J. L. (1987) · New England Journal of Medicine · doi:10.1056/nejm198710083171504 · Cited by 532 · see citing works

Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases

Frentzas, S., Simoneau, È., Bridgeman, V. L., Vermeulen, P., Foo, S., Kostaras, E., Nathan, M. R., Wotherspoon, A. C., Gao, Z., Shi, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4197 · Cited by 456 · see citing works

PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

Patel, J. D., Socinski, M. A., Garon, E. B., Reynolds, C. H., Spigel, D. R., Olsen, M. R., Hermann, R. C., Jotte, R. M., Beck, T., Richards, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.9626 · Cited by 369 · see citing works

Alternative Vascularization Mechanisms in Cancer

Döme, B., Hendrix, M. J. C., Paku, S., Tóvári, J., & Tímár, J. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060302 · Cited by 359 · see citing works

Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab

Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F. F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 318 · see citing works

Pooled Analysis of the Prognostic and Predictive Effects of KRAS Mutation Status and KRAS Mutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy

Shepherd, F. A., Domerg, C., Hainaut, P. L., Janne, P. A., Pignon, J., Graziano, S. L., Douillard, J.-Y., Brambilla, E., Chevalier, T. L., Seymour, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.1390 · Cited by 294 · see citing works

K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways

Scheffler, M., Ihle, M. A., Hein, R., Merkelbach-Bruse, S., Scheel, A. H., Siemanowski, J., Brägelmann, J., Kron, A., Abedpour, N., Ueckeroth, F., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.013 · Cited by 264 · see citing works

ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent.

Mitsudomi, T., Steinberg, S. M., Oie, H. K., Mulshine, J. L., Phelps, R. M., Viallet, J., Pass, H. I., Minna, J. D., & Gazdar, A. F. (1991) · PubMed · Cited by 248 · see citing works

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

Masi, G., Loupakis, F., Salvatore, L., Fornaro, L., Cremolini, C., Cupini, S., Ciarlo, A., Monte, F. D., Cortesi, E., AMOROSO, D., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70175-3 · Cited by 239 · see citing works

The Clinical Benefit of Bevacizumab in Metastatic Colorectal Cancer Is Independent of K-<i>ras</i> Mutation Status: Analysis of a Phase III Study of Bevacizumab with Chemotherapy in Previously Untreated Metastatic Colorectal Cancer

Hurwitz, H. I., Yi, J., Ince, W., Novotny, W. F., & Rosen, O. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0213 · Cited by 239 · see citing works

Oncogenes as inducers of tumor angiogenesis

Rak, J. W., Filmus, J., Finkenzeller, G., Grugel, S., Marm�, D., & Kerbel, R. S. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690598 · Cited by 235 · see citing works

Vessel Co-option Is Common in Human Lung Metastases and Mediates Resistance to Anti-angiogenic Therapy in Preclinical Lung Metastasis Models

Bridgeman, V. L., Vermeulen, P. B., Foo, S., Bilecz, A., Daley, F., Kostaras, E., Nathan, M. R., Wan, E., Frentzas, S., Schweiger, T., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4845 · Cited by 214 · see citing works

Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer

Price, T. J., Hardingham, J. E., Lee, C. K., Weickhardt, A. J., Townsend, A. R., Wrin, J., Chua, A., Shivasami, A., Cummins, M. M., Murone, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5520 · Cited by 210 · see citing works

Predictive Impact of Circulating Vascular Endothelial Growth Factor in Four Phase III Trials Evaluating Bevacizumab

Hegde, P. S., Jubb, A. M., Chen, D., Li, N. F., Meng, Y. G., Bernaards, C., Elliott, R., Scherer, S. J., & Chen, D. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2535 · Cited by 193 · see citing works

Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer: A Systematic Review with Meta-Analysis

Zhan, P., Wang, J., Lv, X.-J., Wang, Q., Qiu, L., Lin, X.-Q., Yu, L.-K., & Song, Y. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181a97e31 · Cited by 192 · see citing works

Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer

Garassino, M. C., Marabese, M., Rusconi, P., Rulli, E., Martelli, O., Farina, G., Scanni, A., & Broggini, M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq680 · Cited by 185 · see citing works

C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.

Kern, J. A., Slebos, R. J. C., Top, B., Rodenhuis, S., Lager, D. J., Robinson, R. A., Weiner, D. B., & Schwartz, D. A. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117001 · Cited by 182 · see citing works

Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia

Rapisarda, A., & Melillo, G. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.64 · Cited by 175 · see citing works

Tumor Islands in Resected Early-stage Lung Adenocarcinomas are Associated With Unique Clinicopathologic and Molecular Characteristics and Worse Prognosis

Onozato, M. L., Kovach, A. E., Yeap, B. Y., Morales‐Oyarvide, V., Klepeis, V. E., Tammireddy, S., Heist, R. S., Mark, E. J., Dias-Santagata, D. C., Iafrate, A. J., et al. (2012) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31826885fb · Cited by 173 · see citing works

K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases

Huncharek, M. S. (1999) · Carcinogenesis · doi:10.1093/carcin/20.8.1507 · Cited by 173 · see citing works

Pharmacological targeting of RAS: recent success with direct inhibitors

O’Bryan, J. P. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.021 · Cited by 153 · see citing works

Non-angiogenic tumours and their influence on cancer biology

Dønnem, T., Reynolds, A. R., Kuczynski, E. A., Gatter, K. C., Vermeulen, P. B., Kerbel, R. S., Harris, A. L., & Pezzella, F. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2018.14 · Cited by 150 · see citing works

Mechanisms of resistance to anti-angiogenesis therapies

Giuliano, S., & Pagès, G. (2013) · Biochimie · doi:10.1016/j.biochi.2013.03.002 · Cited by 140 · see citing works

KRAS Mutations as Prognostic and Predictive Markers in Non–Small Cell Lung Cancer

Martin, P., Leighl, N. B., Tsao, M., & Shepherd, F. A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318283d958 · Cited by 134 · see citing works

VEGF-A Expression Correlates with TP53 Mutations in Non–Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy

Schwaederle, M. C., Lazar, V., Validire, P., Hansson, J., Lacroix, L., Soria, J., Yudi Pawitan, Y., & Kurzrock, R. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2305 · Cited by 123 · see citing works

Phase II Trial of Neoadjuvant Bevacizumab Plus Chemotherapy and Adjuvant Bevacizumab in Patients with Resectable Nonsquamous Non–Small-Cell Lung Cancers

Chaft, J. E., Rusch, V., Ginsberg, M. S., Paik, P. K., Finley, D. J., Kris, M. G., Price, K. A. R., Azzoli, C. G., Fury, M. G., Riely, G. J., et al. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31829923ec · Cited by 122 · see citing works

P53 Mutations in Advanced Cancers: Clinical Characteristics, Outcomes, and Correlation between Progression-Free Survival and Bevacizumab-Containing Therapy

Said, R., Hong, D. S., Warneke, C. L., Lee, J. J., Wheler, J. J., Jankú, F., Naing, A., Falchook, G. S., Fu, S., Piha-Paul, S. A., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.974 · Cited by 115 · see citing works

Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma

Yagi, Y., Aly, R. G. M., Tabata, K., Barlas, A., Rekhtman, N., Eguchi, T., Montecalvo, J., Hameed, M., Manova-Todorova, K. O., Adusumilli, P. S., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.112 · Cited by 96 · see citing works

K-Ras Promotes Angiogenesis Mediated by Immortalized Human Pancreatic Epithelial Cells through Mitogen-Activated Protein Kinase Signaling Pathways

Matsuo, Y., Campbell, P. M., Brekken, R. A., Sung, B., Ouellette, M. M., Fleming, J. B., Aggarwal, B. B., Der, C. J., & Guha, S. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0577 · Cited by 91 · see citing works

Distinct Epidemiology and Clinical Consequence of Classic Versus Rare EGFR Mutations in Lung Adenocarcinoma

Lohinai, Z., Hoda, M. A., Fábián, K., Ostoros, G., Rásó, E., Barbai, T., Tı́már, J., Kovalszky, I., Cserepes, M., Rózsás, A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000492 · Cited by 81 · see citing works

KRAS-mutation incidence and prognostic value are metastatic site-specific in lung adenocarcinoma: poor prognosis in patients with KRAS mutation and bone metastasis

Lohinai, Z., Klikovits, T., Moldvay, J., Ostoros, G., Rásó, E., Tı́már, J., Fábián, K., Kovalszky, I., Kenessey, I., Aigner, C., et al. (2017) · Scientific Reports · doi:10.1038/srep39721 · Cited by 78 · see citing works

Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy

Cserepes, M., Ostoros, G., Lohinai, Z., Rásó, E., Barbai, T., Tı́már, J., Rózsás, A., Moldvay, J., Kovalszky, I., Fábián, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.001 · Cited by 73 · see citing works

KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab

Stremitzer, S., Stift, J., Gruenberger, B., Tamandl, D., Aschacher, T., Wolf, B., Wrba, F., & Gruenberger, T. (2012) · British journal of surgery · doi:10.1002/bjs.8909 · Cited by 72 · see citing works

Limited Tumor Tissue Drug Penetration Contributes to Primary Resistance against Angiogenesis Inhibitors

Torok, S., Rezeli, M., Kelemen, O., Vegvari, A., Watanabe, K., Sugihara, Y., Tisza, A., Marton, T., Kovacs, I., Tovari, J., et al. (2017) · Theranostics · doi:10.7150/thno.16767 · Cited by 70 · see citing works

Vascular Endothelial Growth Factor Levels in Immunodepleted Plasma of Cancer Patients As a Possible Pharmacodynamic Marker for Bevacizumab Activity

Loupakis, F., Falcone, A., Masi, G., Fioravanti, A., Kerbel, R. S., Tacca, M. D., & Bocci, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3051 · Cited by 64 · see citing works

Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy

Döme, B., Tı́már, J., Ladányi, A., Paku, S., Renyi-Vamos, F., Klepetko, W., Láng, G., Döme, P., Bogos, K., & Tóvári, J. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.06.009 · Cited by 63 · see citing works

The clinical relevance of KRAS gene mutation in non-small-cell lung cancer

Tı́már, J. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000051 · Cited by 59 · see citing works

Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer

Chaft, J. E., Dagogo‐Jack, I., Santini, F. C., Eng, J., Yeap, B. Y., Izar, B., Chin, E. N., Jones, D. R., Kris, M. G., Shaw, A. T., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.05.020 · Cited by 57 · see citing works

G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab

Fiala, O., Buchler, T., Mohelnikova-Duchonova, B., Melichar, B., Matejka, V. M., Holubec, L., Kulhankova, J., Bortlicek, Z., Bartouskova, M., Liska, V., et al. (2016) · Tumor Biology · doi:10.1007/s13277-015-4523-7 · Cited by 55 · see citing works

The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease

Shimizu, R., Fujimoto, D., Kato, R., Otoshi, T., Kawamura, T., Tamai, K., Matsumoto, T., Nagata, K., Otsuka, K., Nakagawa, A., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2590-x · Cited by 54 · see citing works

KRAS: Reasons for optimism in lung cancer

Lindsay, C. R., Jamal‐Hanjani, M., Forster, M. D., & Blackhall, F. H. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.001 · Cited by 52 · see citing works

The impact of KRAS mutations on VEGF-A production and tumour vascular network

Figueras, A., Arbos, M. A., Quiles, M., Viñals, F., Germà, J. R., & Capellá, G. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-125 · Cited by 39 · see citing works

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer

Twelves, C. J., Chmielowska, E., Havel, L., Popat, S., Świeboda-Sadlej, A., Sawrycki, P., Bycott, P. W., Ingrosso, A., Kim, S., Williams, J. A., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt489 · Cited by 34 · see citing works

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy

Brady, A. K., McNeill, J. D., Judy, B. F., Bauml, J. M., Evans, T. L., Cohen, R. B., Langer, C. J., Vachani, A., & Aggarwal, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4711 · Cited by 32 · see citing works

Breaking New Ground: The Evolving Concept of Spread through Air Spaces (STAS)

Warth, A., Beasley, M. B., & Mino-Kenudson, M. A. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.020 · Cited by 31 · see citing works

Worse prognosis of KRASc.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx)

Bruera, G., Cannita, K., Giacomo, D. D., Lamy, A., Frébourg, T., Sabourin, J. C., Tosi, M., Alesse, E., Ficorella, C., & Ricevuto, E. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-59 · Cited by 23 · see citing works

The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?

Bruera, G., Cannita, K., Tessitore, A., Russo, A. D., Alesse, E., Ficorella, C., & Ricevuto, E. (2014) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.10.004 · Cited by 23 · see citing works

Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view

Bencsiková, B., Bortlíček, Z., Halámková, J., Ostřížková, L., Kišš, I., Melichar, B., Pavlík, T., Dušek, L., Valík, D., Vyzula, R., et al. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0266-6 · Cited by 21 · see citing works

KRAS-specific Amino Acid Substitutions are Associated With Different Responses to Chemotherapy in Advanced Non–small-cell Lung Cancer

Renaud, S., Guerrera, F., Seitlinger, J., Reeb, J., Voegeli, A., Legrain, M., Mennecier, B., Santelmo, N., Falcoz, P., Quoix, É., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.08.005 · Cited by 16 · see citing works

Bevacizumab in Advanced NSCLC: Chemotherapy Partners and Duration of Use

Gentzler, R. D., Yentz, S. E., & Patel, J. D. (2013) · Current Treatment Options in Oncology · doi:10.1007/s11864-013-0255-3 · Cited by 13 · see citing works

Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer

Ricciuti, B., Brambilla, M., Cortellini, A., Giglio, A. D., Ficorella, C., Sidoni, A., Bellezza, G., Crinò, L., Ludovini, V., Baglivo, S., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02175-y · Cited by 8 · see citing works

Mechanisms that influence tumour response to VEGF-pathway inhibitors

Smith, N. R., Wedge, S. R., Pommier, A., & Barry, S. T. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140261 · Cited by 7 · see citing works

OA03.07 Three-Dimensional Immunofluorescence Analysis of Dynamic Vessel Co-Option of Spread Through Air Spaces (STAS) in Lung Cancer

Yagi, Y., Aly, R. G. M., Tabata, K., Rekhtman, N., Eguchi, T., Montecalvo, J., Manova, K., Adusumilli, P. S., Hameed, M., & Travis, W. D. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.250 · Cited by 4 · see citing works

The efficacy and safety of bevacizumab in addition to platinum‑based chemotherapy for the first‑line treatment of patients with advanced nonsquamous non‑small‑cell lung cancer: Final results of AVALANCHE, an observational cohort study

Tolnay, E., Ghimessy, �., Juh�sz, E., Sztancsik, Z., Losonczy, G., Dombi, P., Vennes, Z., Helf, L., Csada, E., & S�rosi, V. (2018) · Oncology Letters · doi:10.3892/ol.2018.9766 · Cited by 3 · see citing works

Current therapy of KRAS-mutant lung cancer

Ghimessy, A., Radeczky, P., Laszlo, V., Hegedus, B., Renyi-Vamos, F., Fillinger, J., Klepetko, W., Lang, C., Dome, B., & Megyesfalvi, Z. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09903-9 · Cited by 115 · see citing works

Hypoxia Signaling in Cancer: From Basics to Clinical Practice

Sebestyén, A., Kopper, L., Dankó, T., & Tímár, J. (2021) · Pathology and Oncology Research · doi:10.3389/pore.2021.1609802 · Cited by 110 · see citing works

Direct Targeting KRAS Mutation in Non-Small Cell Lung Cancer: Focus on Resistance

Reita, D., Pabst, L., Pencreach, E., Guérin, É., Dano, L., Rimelen, V., Voegeli, A., Vallat, L. D., Mascaux, C., & Beau‐Faller, M. (2022) · Cancers · doi:10.3390/cancers14051321 · Cited by 101 · see citing works

KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup

Xie, M., Xu, X., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672612 · Cited by 76 · see citing works

K-Ras prenylation as a potential anticancer target

Baranyi, M., Buday, L., & Hegedűs, B. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09902-w · Cited by 62 · see citing works

A Precision Medicine Drug Discovery Pipeline Identifies Combined CDK2 and 9 Inhibition as a Novel Therapeutic Strategy in Colorectal Cancer

Somarelli, J. A., Roghani, R. S., Moghaddam, A. S., Thomas, B. C., Rupprecht, G., Ware, K. E., Altunel, E., Mantyh, J. B., Kim, S. Y., McCall, S. J., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0454 · Cited by 39 · see citing works

Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential

Tang, Y., Pu, X., Yuan, X., Pang, Z., Li, F., & Wang, X. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00778-4 · Cited by 37 · see citing works

Investigating hypoxia-inducible factor signaling in cancer: Mechanisms, clinical implications, targeted therapeutic strategies, and resistance

Shaikat, A. H., Azad, S. M. A. K., Tamim, M. A. R., Ullah, M. S., Amin, M. N., Sabbir, M. K., Tarun, M. T. I., Mostaq, M. S., Sabrin, S., Mahmud, M. Z., et al. (2025) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2025.07.003 · Cited by 36 · see citing works

Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer

Shen, M., Qi, R., Ren, J., Lv, D., & Yang, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.780655 · Cited by 29 · see citing works

Structure-based inhibitor design of mutant RAS proteins—a paradigm shift

Nyíri, K., Koppány, G., & Vértessy, B. G. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09914-6 · Cited by 27 · see citing works

Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers

Cekani, E., Epistolio, S., Dazio, G., Cefalì, M., Wannesson, L., Frattini, M., & Froesch, P. (2022) · Cancers · doi:10.3390/cancers14174103 · Cited by 26 · see citing works

Shaping the battlefield: EGFR and KRAS tumor mutations’ role on the immune microenvironment and immunotherapy responses in lung cancer

Alsaed, B., Bobik, N., Laitinen, H. K., Nandikonda, T., Ilonen, I., & Haikala, H. M. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10272-4 · Cited by 25 · see citing works

Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment

Sun, Y., Li, Z., Jian, H., Xia, L., & Lü, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144003 · Cited by 17 · see citing works

The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer

Hung, P.-S., Huang, M.-H., Kuo, Y., & Yang, J. C. (2020) · Cancers · doi:10.3390/cancers12040837 · Cited by 14 · see citing works

First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives

He, Q., Liu, X., Jiang, L., Liu, P., Xuan, W., Wang, Y., Meng, R., Feng, H., Lv, S., Miao, Q., et al. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2441499 · Cited by 13 · see citing works

KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges

Moldvay, J., & Tı́már, J. (2024) · Pathology & Oncology Research · doi:10.3389/pore.2023.1611580 · Cited by 14 · see citing works

Efficacy of first-line chemotherapy combined with immunotherapy or anti-angiogenic therapy in advanced KRAS-mutant non-small cell lung cancer

Qiang, H., Wang, Y., Zhang, Y., Li, J., Zhang, L., Du, H., Ling, X., Cao, S., Zhou, Y., Zhong, R., et al. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102317 · Cited by 9 · see citing works

Clinical characteristics and outcomes of Chinese patients with KRAS‐mutant non‐small cell lung cancer after chemotherapy

Zheng, Y., Lai, Q., Zhao, H., Li, X., Sun, X., & Xing, L. (2021) · 癌症：英文版 · doi:10.1002/cac2.12227 · Cited by 9 · see citing works

Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis

Palmieri, M., Zulato, E., Wahl, S. G. F., Guibert, N. M., & Frullanti, E. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1015161 · Cited by 9 · see citing works

Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC

Cheema, P. K., Banerji, S. O., Blais, N., Chu, Q. S.-C., Juergens, R. A., Leighl, N. B., Sacher, A. G., Sheffield, B. S., Snow, S. L., Vincent, M. D., et al. (2023) · Current Oncology · doi:10.3390/curroncol30070476 · Cited by 9 · see citing works

The prognosis and adjuvant chemotherapy in KRAS mutation patients with stage I lung adenocarcinoma

Ma, S., Li, K., Wang, R.-R., Qian, J., Fan, Y., Qin, X., Li, M., & Wu, L. (2024) · Clinical Surgical Oncology · doi:10.1016/j.cson.2024.100069 · Cited by 5 · see citing works

Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients

Wang, M., Li, J., Xu, S., Li, Y., Li, J., Yu, J., Tang, X., & Zhu, H. (2022) · Cancer Medicine · doi:10.1002/cam4.5356 · Cited by 5 · see citing works

SGPP2 is activated by SP1 and promotes lung adenocarcinoma progression

Yang, X., & Wang, C. (2024) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001648 · Cited by 4 · see citing works

Impact of MEK inhibition on T-cell infiltration and function after radiotherapy in KRAS-mutant lung cancer

Zheng, Y., Su, C., Pan, J., Wang, Y., Zhao, M., Zhang, M., Yan, P., Liu, N., & Sun, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1663502 · Cited by 3 · see citing works

The Effect of the Kirsten Rat Sarcoma Viral Oncogene Homolog ( Kras ) Proto-Oncogene, GTPase Genetic Polymorphism on the Safety and Efficacy of Bevacizumab Combination Treatment Regimens for Patients with Nonsquamous, Non-Small Cell Lung Cancer with Brain Metastases

Song, Z., Ren, G., Wang, X., & Hu, L. (2022) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2021.0219 · Cited by 2 · see citing works

Exploration of efficacy of different therapy regimens for advanced NSCLC patients with KRAS mutation in the first-line treatment

Wang, K., Xu, M., Wang, Y., Xu, C., Hao, Y., & Song, Z. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03485-6 · Cited by 1 · see citing works

Bioinformatic analysis linking genomic defects to chemosensitivity and mechanism of action

Covell, D. G. (2021) · PLoS ONE · doi:10.1371/journal.pone.0243336

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy

Brady, A. K., McNeill, J. D., Judy, B. F., Bauml, J. M., Evans, T. L., Cohen, R. B., Langer, C. J., Vachani, A., & Aggarwal, C. (2015) · Oncotarget · doi:10.18632/oncotarget.4711 · Cited by 32 · see citing works

Kras Status as Predictive Marker of Response and Time to Progression in EGFR Wild-Type Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Platin-Docetaxel-Bevacizumab

Dómine, M., Rojo, F., Izarzugaza, Y., Zazo, S., Lobo, F., Aceñero, M. J. F., Madoz, J., Casado, V., Rubio, G., & García‐Foncillas, J. (2012) · Annals of Oncology · doi:10.1016/s0923-7534(20)32758-7

KRAS mutations as predictive biomarker in patients with EGFR wild-type stage IV nonsquamous non-small cell lung cancer (NSCLC) recruited in a phase II clinical study with carboplatin-docetaxel-bevacizumab.

Dómine, M., Izarzugaza, Y., Rojo, F., Lobo, F., Fernández‐Aceñero, M. J., Casado, V., Rubio, G., Arranz, J. L., León, A., Martin-Valades, J. I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.e18069 · Cited by 1 · see citing works

Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A retrospective study of patients treated with platinum-based chemotherapy

Cserepes, M., Ostoros, G., Lohinai, Z., Rásó, E., Barbai, T., Tı́már, J., Rózsás, A., Moldvay, J., Kovalszky, I., Fábián, K., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.001 · Cited by 73 · see citing works

Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis

Garde, J., Lewintre, E. J., Gil-Raga, M., Evgenyeva, E., Escalante, S. M., Llombart‐Cussac, A., & Camps, C. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1149 · Cited by 10 · see citing works